These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 25459104)

  • 41. Bupropion and naltrexone combination alters high fructose corn syrup self-administration and gene expression in rats.
    Levy A; Daniels S; Hudson R; Horman T; Flynn A; Zhou Y; Leri F
    Neuropharmacology; 2018 Jun; 135():547-554. PubMed ID: 29408463
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Route of administration affects the ability of naltrexone to reduce amphetamine-potentiated brain stimulation reward in rats.
    Todtenkopf MS; O'Neill KS; Kriksciukaite K; Turncliff RZ; Dean RL; Ostrovsky-Day I; Deaver DR
    Addict Biol; 2009 Sep; 14(4):408-18. PubMed ID: 19489752
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Discriminative-stimulus, subject-rated, and physiological effects of methamphetamine in humans pretreated with aripiprazole.
    Sevak RJ; Vansickel AR; Stoops WW; Glaser PE; Hays LR; Rush CR
    J Clin Psychopharmacol; 2011 Aug; 31(4):470-80. PubMed ID: 21694622
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Contrave, a bupropion and naltrexone combination therapy for the potential treatment of obesity.
    Padwal R
    Curr Opin Investig Drugs; 2009 Oct; 10(10):1117-25. PubMed ID: 19777400
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Naltrexone attenuates the subjective effects of amphetamine in patients with amphetamine dependence.
    Jayaram-Lindström N; Konstenius M; Eksborg S; Beck O; Hammarberg A; Franck J
    Neuropsychopharmacology; 2008 Jul; 33(8):1856-63. PubMed ID: 17957221
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Bupropion and naltrexone: a review of their use individually and in combination for the treatment of obesity.
    Plodkowski RA; Nguyen Q; Sundaram U; Nguyen L; Chau DL; St Jeor S
    Expert Opin Pharmacother; 2009 Apr; 10(6):1069-81. PubMed ID: 19364254
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Safety of intravenous methamphetamine administration during treatment with bupropion.
    Newton TF; Roache JD; De La Garza R; Fong T; Wallace CL; Li SH; Elkashef A; Chiang N; Kahn R
    Psychopharmacology (Berl); 2005 Nov; 182(3):426-35. PubMed ID: 16163531
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Combination therapy with naltrexone and bupropion for obesity reduces total and visceral adiposity.
    Smith SR; Fujioka K; Gupta AK; Billes SK; Burns C; Kim D; Dunayevich E; Greenway FL
    Diabetes Obes Metab; 2013 Sep; 15(9):863-6. PubMed ID: 23489381
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Naltrexone sustained-release (SR) + bupropion SR combination therapy for the treatment of obesity: 'a new kid on the block'?
    Katsiki N; Hatzitolios AI; Mikhailidis DP
    Ann Med; 2011 Jun; 43(4):249-58. PubMed ID: 21254901
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Bupropion attenuates methamphetamine self-administration in adult male rats.
    Reichel CM; Murray JE; Grant KM; Bevins RA
    Drug Alcohol Depend; 2009 Feb; 100(1-2):54-62. PubMed ID: 19010609
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Low-dose naltrexone for the treatment of fibromyalgia: findings of a small, randomized, double-blind, placebo-controlled, counterbalanced, crossover trial assessing daily pain levels.
    Younger J; Noor N; McCue R; Mackey S
    Arthritis Rheum; 2013 Feb; 65(2):529-38. PubMed ID: 23359310
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the behavioral effects of bupropion and psychostimulants.
    Mori T; Shibasaki M; Ogawa Y; Hokazono M; Wang TC; Rahmadi M; Suzuki T
    Eur J Pharmacol; 2013 Oct; 718(1-3):370-5. PubMed ID: 23993950
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Naltrexone ER/Bupropion ER: A Review in Obesity Management.
    Greig SL; Keating GM
    Drugs; 2015 Jul; 75(11):1269-80. PubMed ID: 26105116
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers.
    Oliveto A; McCance-Katz FE; Singha A; Petrakis I; Hameedi F; Kosten TR
    Drug Alcohol Depend; 2001 Jul; 63(2):155-67. PubMed ID: 11376920
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Methamphetamine Use: A New Wave in the Opioid Crisis?
    Fogger SA
    J Addict Nurs; 2019; 30(3):219-223. PubMed ID: 31478970
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A double-blind, placebo-controlled study of N-acetyl cysteine plus naltrexone for methamphetamine dependence.
    Grant JE; Odlaug BL; Kim SW
    Eur Neuropsychopharmacol; 2010 Nov; 20(11):823-8. PubMed ID: 20655182
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Effects of naltrexone on response to intravenous cocaine, hydromorphone and their combination in humans.
    Walsh SL; Sullivan JT; Preston KL; Garner JE; Bigelow GE
    J Pharmacol Exp Ther; 1996 Nov; 279(2):524-38. PubMed ID: 8930154
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of baclofen alone and in combination with naltrexone on ethanol consumption in the rat.
    Stromberg MF
    Pharmacol Biochem Behav; 2004 Aug; 78(4):743-50. PubMed ID: 15301930
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Baclofen does not alter the reinforcing, subject-rated or cardiovascular effects of intranasal cocaine in humans.
    Lile JA; Stoops WW; Allen TS; Glaser PE; Hays LR; Rush CR
    Psychopharmacology (Berl); 2004 Feb; 171(4):441-9. PubMed ID: 14504683
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of naltrexone and Ro 15-4513 on a multiple schedule of ethanol and Tang self-administration.
    Shelton KL; Grant KA
    Alcohol Clin Exp Res; 2001 Nov; 25(11):1576-85. PubMed ID: 11707632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.